Yersinia Enterocolitica

Dosage for Yersinia Enterocolitica allergenic extract is highly individualized and is not based on body weight, but rather on the patient's sensitivity level.

• Skin Prick Testing: Typically, one drop of the extract (concentration often 1:10 or 1:20 w/v) is applied to the forearm or back. A sterile lancet is used to prick the skin through the drop. A positive control (histamine) and a negative control (saline/glycerin) must be used simultaneously for comparison.
• Intradermal Testing: If the prick test is negative, an intradermal injection of 0.02 mL to 0.05 mL of a 1:100 or 1:1000 dilution may be administered. The dose is adjusted based on the patient's history of reactivity.
• Immunotherapy (Off-Label): If used for desensitization, the starting dose is usually 0.1 mL of an extremely high dilution (e.g., 1:100,000). Doses are increased weekly by 0.1 mL increments until a maintenance dose is reached, typically 0.5 mL of a 1:100 or 1:10 concentration.

Yersinia Enterocolitica extract is not specifically FDA-approved for pediatric use, but it is used in clinical practice by pediatric allergists. Dosing is generally similar to adult dosing in terms of volume (0.02 mL for intradermal), but extreme caution is exercised. Children may have more reactive skin, and the risk of a systemic reaction must be weighed against the diagnostic benefit. There is no established safety profile for children under the age of 2.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the extract is not cleared by the kidneys in a manner that affects its activity or toxicity.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic impairment. The metabolism of bacterial antigens is independent of liver function.

Elderly Patients

Elderly patients may exhibit reduced skin reactivity (decreased wheal and flare response) due to age-related changes in skin mast cell density and vascular responsiveness. While the dose remains the same, the interpretation of the results must be handled with caution by the healthcare provider.

This product is never self-administered by the patient. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

• Preparation: The skin site (usually the volar surface of the forearm) is cleaned with alcohol and allowed to dry.
• Administration: For prick tests, the lancet should not cause bleeding. For intradermal tests, a 26- or 27-gauge needle is inserted at a 15-degree angle to create a small 'bleb' under the skin.
• Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It should never be frozen, as freezing can denature the proteins and render the extract ineffective.

In the context of diagnostic testing, a missed appointment simply delays the diagnosis. In the context of immunotherapy, a missed dose can be critical. If a dose is missed by more than 7 days, the physician may need to reduce the next dose to prevent an allergic reaction. If missed by more than 4 weeks, the protocol may need to be restarted from the beginning.

An 'overdose' in the context of allergenic extracts refers to the administration of a concentration higher than the patient's tolerance level, leading to a systemic allergic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, rapid heart rate, or a sharp drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids as directed by the emergency medical protocol.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not attempt to use this product outside of a controlled medical environment.

Local reactions are the most frequent side effects associated with Yersinia Enterocolitica allergenic extract. These are generally expected as part of the diagnostic process.

• Wheal and Flare: A raised, itchy bump (wheal) surrounded by a red area (flare). This typically peaks at 15-20 minutes and resolves within a few hours.
• Local Pruritus: Intense itching at the site of the skin test or injection.
• Erythema: Redness of the skin that may extend several centimeters from the test site.
• Burning Sensation: A mild, transient stinging immediately following the injection, often attributed to the preservative (phenol) or the stabilizer (glycerin).

• Delayed Local Swelling: Swelling and redness that appears 6 to 24 hours after the test. This is often warm to the touch and may be slightly painful.
• Lymphangitis: Red streaks extending from the injection site toward the lymph nodes, indicating a localized inflammatory response.
• Subcutaneous Nodules: Small, hard lumps under the skin at the injection site that may persist for several days or weeks.

• Systemic Urticaria: Hives appearing on parts of the body far away from the injection site.
• Syncope: Fainting or lightheadedness, often due to a vasovagal response (fear of needles) rather than the extract itself.
• Headache and Fatigue: Some patients report a 'flu-like' feeling for 24 hours following extensive skin testing.

> Warning: Stop the procedure and call for emergency help immediately if you experience any of the following symptoms of a systemic allergic reaction (anaphylaxis):

• Respiratory Distress: Difficulty breathing, shortness of breath, or a feeling of 'tightness' in the chest.
• Upper Airway Obstruction: Hoarseness, stridor (high-pitched breathing sound), or swelling of the tongue and throat.
• Cardiovascular Collapse: Dizziness, confusion, rapid or weak pulse, and a sudden drop in blood pressure (hypotension).
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after administration.

Because Yersinia Enterocolitica extract is typically used for short-term diagnostic purposes, long-term side effects are rare. However, in patients receiving long-term immunotherapy, there is a theoretical risk of developing persistent granulomas at the injection site or, very rarely, the development of new sensitivities to other components in the extract.

While non-standardized extracts like Yersinia Enterocolitica may not always carry a specific boxed warning in the same way as high-potency standardized extracts, the class-wide warning for allergenic extracts applies:

WARNING: RISK OF ANAPHYLAXIS

Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes following administration. This product should only be administered by physicians who are exceptionally experienced in the treatment of systemic reactions and have the necessary equipment (epinephrine, oxygen, airway management) available immediately.

Report any unusual symptoms or persistent reactions to your healthcare provider immediately. Local reactions that exceed 10 cm in diameter should be reported before the next dose is administered.

Yersinia Enterocolitica allergenic extract is a potent biological substance. It is not a vaccine and does not provide immunity against yersiniosis. It is strictly a diagnostic and immunological tool. Patients with a history of severe asthma or those currently experiencing an asthma exacerbation are at a significantly higher risk for severe systemic reactions and should generally avoid skin testing until their condition is stabilized.

No specific FDA black box warning exists uniquely for Yersinia Enterocolitica, but it falls under the general mandate for all allergenic extracts regarding the risk of sudden, life-threatening anaphylaxis. The presence of a physician and a 30-minute post-injection observation period is mandatory.

• Allergic Reactions / Anaphylaxis Risk: The risk is highest in patients with high levels of pre-existing IgE. Even a tiny amount of extract can trigger a full-body reaction in highly sensitive individuals.
• Asthma Status: Patients with unstable or poorly controlled asthma (FEV1 < 80% of predicted) are at the greatest risk for fatal outcomes if a systemic reaction occurs. Testing should be postponed if the patient is symptomatic.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat. This is a critical safety consideration.
• Autoimmune Disorders: Use with caution in patients with active autoimmune diseases, as the introduction of bacterial antigens could theoretically trigger a flare-up of the underlying condition.

• Immediate Observation: The patient must remain in the clinic for at least 30 minutes after the last test or injection.
• Peak Flow Monitoring: For patients with asthma, a peak flow meter may be used before and after testing to ensure no bronchospasm has occurred.
• Site Inspection: The healthcare provider will measure the size of the wheal and flare (in millimeters) and record the results in the clinical chart.

Generally, Yersinia Enterocolitica extract does not affect the ability to drive. However, if a patient experiences a vasovagal reaction (fainting) or a mild systemic reaction, they should not drive until they have fully recovered and been cleared by the medical staff.

Alcohol should be avoided for 24 hours before and after testing. Alcohol can increase blood flow to the skin (vasodilation), which may lead to larger-than-normal skin reactions or potentially accelerate the systemic absorption of the extract, increasing the risk of side effects.

There are no withdrawal symptoms associated with discontinuing Yersinia Enterocolitica extract. However, if a patient is undergoing a desensitization protocol, stopping the treatment will result in the loss of immunological tolerance over time.

> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Yersinia Enterocolitica testing.

• Beta-Adrenergic Blockers: While not strictly contraindicated in all settings, the combination of allergenic extracts and beta-blockers is highly dangerous. If a patient on a beta-blocker has an anaphylactic reaction to the Yersinia extract, the beta-blocker will prevent epinephrine from working effectively, which can lead to death. Many specialists require patients to switch to an alternative antihypertensive before testing.

• ACE Inhibitors: There is evidence that patients taking ACE inhibitors (e.g., lisinopril) may be at higher risk for more severe or prolonged anaphylactic reactions, particularly angioedema (severe swelling).
• MAO Inhibitors: Monoamine oxidase inhibitors (used for depression) can potentiate the effects of epinephrine if it needs to be administered, potentially leading to a hypertensive crisis.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can increase the body's sensitivity to epinephrine, complicating the management of an allergic reaction.

• Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), and diphenhydramine (Benadryl) MUST be stopped 3 to 7 days before skin testing. These drugs block the H1 receptors in the skin, which will prevent the 'wheal and flare' from appearing, leading to a false-negative result.
• H2 Blockers: Medications like famotidine (Pepcid) can also partially suppress skin reactions and should be discontinued 48 hours before testing.
• Systemic Corticosteroids: Long-term use of oral prednisone can thin the skin and suppress the immune response, potentially masking a positive test result.

• High-Histamine Foods: Consuming foods high in histamine (aged cheeses, red wine, fermented foods) immediately before testing may theoretically increase skin reactivity, though this is not clinically standardized.
• Caffeine: High doses of caffeine may slightly increase heart rate, which could complicate the assessment of a patient if they begin to feel anxious or have a mild reaction.

• St. John's Wort: May interact with various medications used to treat allergic reactions.
• Astragalus/Echinacea: These immune-stimulating herbs could theoretically alter the skin's response to bacterial antigens, although clinical data is lacking.

• Skin Test Interference: The most significant 'interaction' is with the skin test itself. Any drug that stabilizes mast cells or blocks histamine will interfere with the diagnostic accuracy of the Yersinia Enterocolitica extract.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'over-the-counter' allergy or cold medicines.

• Previous Severe Systemic Reaction: If a patient has ever had an anaphylactic reaction to Yersinia Enterocolitica extract or any of its components (such as phenol or glycerin), they must never receive it again. The risk of a fatal repeat reaction is too high.
• Unstable Asthma: Patients with an FEV1 less than 80% of their predicted value or those who have required emergency care for asthma in the last 3 months should not undergo testing. A systemic reaction in these patients is frequently fatal.
• Acute Infection: Testing should not be performed while a patient is suffering from an acute febrile illness, as the immune system is already in a state of high activation.

• Pregnancy: While not an absolute contraindication, skin testing is generally avoided during pregnancy unless the diagnostic information is critical for the mother's immediate health. The risk is not to the fetus directly from the extract, but from the potential for maternal anaphylaxis and the subsequent drop in oxygen/blood pressure to the fetus.
• Severe Atopic Dermatitis: If the skin is extensively inflamed or covered in eczema, there may not be enough 'clear' skin to perform an accurate test, and the background redness may make the results impossible to read.
• Beta-Blocker Therapy: As noted in the interactions section, this is a major safety concern that requires a risk-benefit analysis by the physician.

Patients who are allergic to other members of the Yersiniaceae family (such as Yersinia pseudotuberculosis) may show cross-reactivity to the Yersinia Enterocolitica extract. Additionally, patients with sensitivities to certain Gram-negative bacterial components may exhibit non-specific irritant reactions.

> Important: Your healthcare provider will evaluate your complete medical history and current medication list before deciding if Yersinia Enterocolitica testing is safe for you.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Yersinia Enterocolitica allergenic extract in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether the extract can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The primary concern is the risk of systemic anaphylaxis in the mother, which can cause fetal hypoxia (lack of oxygen). Most allergists recommend postponing diagnostic skin testing until after delivery.

It is not known whether the antigens in Yersinia Enterocolitica extract are excreted in human milk. Because many drugs and biological proteins are excreted in human milk, caution should be exercised. However, since the amount of protein injected during a skin test is microscopic, the risk to a nursing infant is considered extremely low. The decision to test should be based on clinical necessity.

Safety and effectiveness in children under the age of 2 have not been established. In older children, the extract is used similarly to adults, but with smaller volumes for intradermal testing. Children should be closely monitored as they may be less able to articulate the early symptoms of a systemic reaction (such as an itchy throat or a feeling of 'doom').

Clinical studies of Yersinia Enterocolitica extract did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, elderly patients have thinner skin and fewer mast cells, which can lead to smaller wheal sizes. Physicians should be aware that a 'negative' test in an elderly patient may not always rule out sensitivity.

No specific studies have been performed in patients with renal impairment. However, since the extract is a biological protein that is degraded locally and not primarily excreted by the kidneys, renal failure is not expected to affect the safety or efficacy of the diagnostic test.

No studies have been performed in patients with hepatic impairment. The liver does not play a primary role in the clearance of locally administered allergenic proteins, so no dosage adjustments are necessary for patients with liver disease.

> Important: Special populations require individualized medical assessment and a cautious approach to immunological testing.

Yersinia Enterocolitica allergenic extract acts as a diagnostic antigen. When introduced into the skin, it bypasses the primary physical barriers of the immune system and interacts directly with resident immune cells. In a sensitized individual, the extract's proteins (antigens) bind to IgE antibodies on the surface of mast cells. This triggers the release of pre-formed mediators (histamine) and the synthesis of new mediators (leukotrienes). These chemicals cause local vasodilation (redness) and increased capillary permeability (swelling), creating the characteristic wheal and flare. This is a classic Type I hypersensitivity reaction.

The onset of the pharmacodynamic effect (the skin reaction) is rapid, occurring within 5 to 10 minutes of administration and peaking at 15 to 20 minutes. The duration of the visible effect is usually 2 to 4 hours. There is no evidence of tolerance development with single diagnostic doses, although repeated administration in an immunotherapy context is designed to induce 'immunological tolerance' by shifting the immune response from a Th2 (allergic) to a Th1 (protective) or Treg (regulatory) profile.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local administration) |

| Protein Binding | Minimal (Local tissue binding) |

| Half-life | 2-6 hours (Immunological signal) |

| Tmax | 15-20 minutes (Skin reaction) |

| Metabolism | Local proteolytic degradation |

| Excretion | Lymphatic clearance |

• Molecular Formula: Complex mixture of bacterial proteins and polysaccharides.
• Molecular Weight: Variable (ranges from 10 kDa to >100 kDa for various Yop proteins).
• Solubility: Soluble in aqueous solutions and 50% glycerin.
• Structure: The extract contains various cellular components of Yersinia enterocolitica, including the cell wall, lipopolysaccharides, and outer membrane proteins.

Yersinia Enterocolitica is classified as a Non-Standardized Allergenic Extract. It belongs to the broader category of Biologicals and Immunological Agents. Related medications in this class include other bacterial extracts (e.g., Staphylococcus aureus extract) and fungal extracts (e.g., Alternaria or Aspergillus extracts).